PLUS1
72.33
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Afterhours (Closed)
Low
37.88
High
100.77
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
Level 1 Starter
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd | BHVN | NYSE | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| 0.00 | 0.0% | 72.33 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 72.33 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 72.33 | USD |
Biohaven Pharmaceutical Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 4.35B | 60.15M | 44.14M | $ - | $ - | -10.99 | -6.50 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Biohaven Pharmaceutical News
| Date | Time | Source | News Article |
|---|---|---|---|
| 4/13/2021 | 16:35 | Edgar (US Regulatory) | Additional Proxy Soliciting Materials (definitive) (defa14a) |
| 4/13/2021 | 07:30 | PR Newswire (US) | Biohaven Highlights Neuroscience Advancements with 22.. |
| 4/08/2021 | 16:44 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 4/07/2021 | 07:30 | PR Newswire (US) | Biohaven Announces Preliminary 1Q2021 Net Product Revenue.. |
| 4/06/2021 | 07:30 | PR Newswire (US) | Rick Ware Racing, Biohaven's Nurtec ODT and Nine Line.. |
| 4/06/2021 | 06:05 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 3/29/2021 | 07:44 | Seeking Alpha | Biohaven enrolls first patient in oral zavegepant study in.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BHVN Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 70.77 | 76.91 | 70.08 | 73.90 | 485,704 | 1.56 | 2.2% |
| 1 Month | 72.82 | 76.91 | 62.57 | 69.22 | 648,767 | -0.49 | -0.67% |
| 3 Months | 87.00 | 93.539 | 62.57 | 76.95 | 633,315 | -14.67 | -16.86% |
| 6 Months | 77.99 | 100.77 | 62.57 | 81.93 | 612,892 | -5.66 | -7.26% |
| 1 Year | 37.92 | 100.77 | 37.88 | 72.03 | 633,860 | 34.41 | 90.74% |
| 3 Years | 27.18 | 100.77 | 25.60 | 53.76 | 625,366 | 45.15 | 166.11% |
| 5 Years | 20.00 | 100.77 | 16.5001 | 49.33 | 566,468 | 52.33 | 261.65% |
Biohaven Pharmaceutical Description
| Biohaven Pharmaceutical Holding Co Ltd is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipeline products include BHV3000-301, BHV3000-302, BHV3000-303, and others. |
